Literature DB >> 19699532

Clinical course and prognosis of trochlear nerve schwannomas.

Valerie I Elmalem1, Brian R Younge, Valérie Biousse, Jacqueline A Leavitt, Mark L Moster, Judith Warner, Mark J Kupersmith, Klara Landau, Michael C Brodsky, Larry P Frohman, Eugene F May, Robert L Tomsak, Nancy J Newman.   

Abstract

PURPOSE: To delineate the disease course and prognosis of patients with mass lesions of the fourth nerve presumed to be schwannomas.
DESIGN: Nonrandomized retrospective case series. PARTICIPANTS: Thirty-seven consecutive cases of presumed trochlear nerve schwannoma from 9 tertiary university neuro-ophthalmology centers.
METHODS: Cases were collected, and their clinical characteristics on presentation and follow-up are described. Inclusion criteria were brain magnetic resonance imaging (MRI) with a lesion suggestive of a schwannoma along the course of the fourth nerve. Exclusion criteria were other causes of fourth nerve palsy, such as congenital, traumatic or microvascular; normal (or lack of) initial brain MRI; lack of adequate clinical information; and disappearance of the lesion on subsequent follow-up brain MRI. MAIN OUTCOME MEASURES: Demographics of patients, presence of neurofibromatosis, symptoms on presentation, vertical deviation, lesion size (on presentation and follow-up), length of follow-up, and outcomes of treatment for lesions or diplopia.
RESULTS: Seven patients were excluded and of the 30 patients included in our series, patients were predominantly male (77%) with a mean age of 51 years (range 9-102 years). In contrast with prior case reports, almost all of our cases had a fourth nerve palsy on presentation (29/30), often isolated. Mean follow-up was 3.1 years (range 0.2 months to 11.1 years). There was no significant difference between initial and follow-up lesion size (4.4 vs. 5 mm) for patients who did not receive treatment of lesions (P = 0.36). Only 3 patients underwent neurosurgical resection and an additional patient received gamma-knife radiotherapy. The majority of patients (24/30) did not pursue strabismus surgery for vertical diplopia.
CONCLUSIONS: Patients with isolated fourth nerve palsy and small lesions of the fourth nerve have a good prognosis and should be followed with serial MRI scans without neurosurgical intervention unless they develop signs of brain stem compression. Most patients with diplopia and benign fourth nerve lesions typical of trochlear nerve schwannoma can adapt with either prism spectacles or no treatment at all, although strabismus surgery can be successful.

Entities:  

Mesh:

Year:  2009        PMID: 19699532     DOI: 10.1016/j.ophtha.2009.03.054

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

Review 1.  An unusual case of binocular oblique diplopia in an 82-year-old man.

Authors:  Gaurav Jindal; Aubrey Gilbert; Rafeeque Bhadelia; Nurhan Torun
Journal:  Digit J Ophthalmol       Date:  2015-09-12

Review 2.  Schwannoma of the trochlear nerve-an illustrated case series and a systematic review of management.

Authors:  Nurhan Torun; Yosef Laviv; Kianush Karimian Jazi; Anand Mahadevan; Rafeeque A Bhadelia; Anderson Matthew; Mitchell Strominger; Ekkehard M Kasper
Journal:  Neurosurg Rev       Date:  2016-09-01       Impact factor: 3.042

3.  Isolated schwannoma involving extraocular muscles.

Authors:  Fatma Yulek; Joseph L Demer
Journal:  J AAPOS       Date:  2016-07-14       Impact factor: 1.220

4.  Dumbbell-shaped abducens schwannoma: case report.

Authors:  Shunsuke Shibao; Saeko Hayashi; Kazunari Yoshida
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-11-08       Impact factor: 1.742

5.  Trochlear Nerve Schwannoma Treated with Gamma Knife after Excision: A Case Report and Review of the Literature.

Authors:  Takuro Inoue; Ayako Shima; Hisao Hirai; Fumio Suzuki; Masayuki Matsuda
Journal:  J Neurol Surg Rep       Date:  2015-09-09

6.  Recurrent isolated oculomotor nerve palsy caused by schwannoma in a pediatric patient.

Authors:  Donghun Lee; Won Jae Kim; Myung Mi Kim
Journal:  Indian J Ophthalmol       Date:  2018-09       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.